CHRS Q2 2024 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$65M+10.7% YoY

Gross Profit

$35M54.5% margin

Operating Income

-$21M-31.6% margin

Net Income

-$13M-19.9% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+2715.4%

Cash Flow

Operating Cash Flow

$60M

Free Cash Flow

$60M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$675M

Total Liabilities

$759M

Stockholders' Equity

-$84M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$59M	+10.7%
Gross Profit	$35M	$34M	+4.6%
Operating Income	-$21M	-$35M	+40.6%
Net Income	-$13M	-$43M	+69.9%

Revenue Segments

Product Revenue

$58M90%

Other

$7M10%